Novel angiogenesis therapeutics by redox injectable hydrogel - Regulation of local nitric oxide generation for effective cardiovascular therapy

Biomaterials. 2018 Jun:167:143-152. doi: 10.1016/j.biomaterials.2018.03.023. Epub 2018 Mar 13.

Abstract

Nitric oxide (NO) possesses various functions in cardiovascular diseases; however, due to an extremely short half-life and low bioavailability, its therapeutic application is limited. In inflamed tissues, overproduced reactive oxygen species (ROS) rapidly react with the endogenous NO, reducing its bioavailability. Here, we developed a controllable NO-releasing redox injectable hydrogel (NO-RIG) formed by the electrostatic crosslinking between the polyion complex flower-type micelles composing of functional polymers to scavenge overproduced ROS and regulate the local NO expression level simultaneously. After the intracardiac injection to mice, NO-RIG converted to gel via physiological temperature-responsive character, distributed homogeneously, and retained in the myocardial tissue for more than 10 d. Treatment with NO-RIG remarkably decreased the infarction size and improved the heart function after myocardial infarction when compared to control injectable hydrogels, such as a simple NO-releasing or ROS-scavenging injectable gels. We found that NO-RIG treatment significantly enhanced the angiogenesis and new blood vessels formation in mice through the regulation of the NO sustained release and redox equilibrium. NO-RIG presents high potential in preventing and treating cardiovascular diseases.

Keywords: Myocardial infarction; Nitric oxide delivery; Polyion complex micelle; Reactive oxygen species; Redox injectable hydrogel.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inducing Agents / administration & dosage*
  • Angiogenesis Inducing Agents / therapeutic use
  • Animals
  • Delayed-Action Preparations / chemistry*
  • Hydrogels / chemistry*
  • Injections
  • Male
  • Mice
  • Mice, Inbred ICR
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / metabolism
  • Myocardial Infarction / pathology
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / administration & dosage*
  • Nitric Oxide Donors / therapeutic use
  • Oxidation-Reduction
  • RAW 264.7 Cells
  • Reactive Oxygen Species / metabolism

Substances

  • Angiogenesis Inducing Agents
  • Delayed-Action Preparations
  • Hydrogels
  • Nitric Oxide Donors
  • Reactive Oxygen Species
  • Nitric Oxide